Savolitinib and osimertinib combination significantly improves PFS in EGFR-mutated NSCLC with MET amplification compared to ...

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) ...

The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...

Brain metastases are a common problem in patients with EGFR-mutated non-small cell lung cancer (NSCLC), occurring in about one-fifth to one-quarter of patients. Many brain metastases will be ...

Patients prescribed the combination therapy should be given anticoagulant prophylaxis to prevent VTE during the first 4 months of treatment. The Food and Drug Administration (FDA) has approved ...

ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why AVBP stock is a Buy.

NEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of ...

Dr. Jacob Sands discusses the significance of the FDA approval of Datroway for the treatment of patients with locally advanced or metastatic EGFR+ NSCLC. On June 23, 2025, the U.S. Food and Drug ...

The Food and Drug Administration will speed up their review and potential approval of Tagrisso for certain patients with EGFR-mutant lung cancer. The Food and Drug Administration (FDA) granted a ...

First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment — — Savolitinib ...